Here is a short free full text article describing the outcomes of the 2010–17 Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET) study. The study compares inhibitor incidence arising from rFVIII (recombinant) concentrate compared to pdFVIII (plasma-derived) concentrate. Further, in an important addition to hemophilia therapy protocol, SIPPET also compares inhibitor incidence in hemophilic F8 null versus non-null genotypes.
Rosendaal FR, Palla R, Garagiola I, Mannucci PM, Peyvandi F. for the SIPPET Study Group. Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. Blood. 2017;130:1757–9.
No comments here.